Table 4 Results of AUCR analysis and C-maxR based on the PBPK model.

From: A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions

Dose (bid)

AUC Relative Ratio (AUCR) 

Max Concentration Ratio (C_maxR)

0.15mg/kg

1.97 (95% CI 1.84-2.10, p < 0.01)

1.59 (95% CI 1.51-1.67, p < 0.01)

0.2mg/kg

1.44 (95% CI 1.39-1.49, p < 0.01)

1.45 (95% CI 1.40-1.50, p < 0.01)

0.3mg/kg

1.20 (95% CI 1.18-1.22, p < 0.01)

1.23 (95% CI 1.21-1.25, p < 0.01)

Type

Tacrolimus CYP2C19 EM

Tacrolimus CYP2C19 IM

Tacrolimus CYP2C19 PM

Tacrolimus CYP3A4 PM

AUCR

1.97 (95% CI 1.84-2.10, p < 0.01)

3.50 (95% CI 3.36-3.63, p < 0.01)

20.27 (95% CI 9.724-30.81, p < 0.01)

2.22 (95% CI 2.07-2.39, p < 0.01)

C_maxR

1.59 (95% CI 1.51-1.67, p < 0.01)

2.88 (95% CI 2.80-2.96, p < 0.01)

5.18 (95% CI 4.49-5.87, p < 0.01)

1.86 (95% CI 1.75-1.97, p < 0.01)

Back to article page